TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15526247

Group type: EXPERIMENTAL
Intervention: ARB, irbesartan
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: ACE inhibitor, captopril
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (normal healthy controls)
Number of subjects: 68
Study: 10902932

Group type: EXPERIMENTAL
Intervention: Staged decompression while breathing 100% oxygen (SD100) with 15 min of ground-level preoxygenation and an additional 60 or 120 min of SD100 at altitudes between 8,000 ft and 18,000 ft.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control exposures with 75- or 135-min ground-level preoxygenation.
Number of subjects: 30
Study: 9315176

Group type: EXPERIMENTAL
Intervention: Funisocentesis
Number of subjects: 41
Study: 8366821

Group type: EXPERIMENTAL
Intervention: IVIG (250 mg/Kg on the first and seventh day after admission)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sterile saline (placebo)
Number of subjects: 40
Study: 3771829

Group type: EXPERIMENTAL
Intervention: Single reminder for high scorers on the TEQ
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two reminders for low scorers on the TEQ
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postcard reminders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telephone reminders
Number of subjects: 0
Study: 30822311

Group type: EXPERIMENTAL
Intervention: Continuous sine wave single-frequency stimulation (40 Hz) for 30 minutes, five days per week, over five weeks, concomitant with usual care.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Random and intermittent complex wave gamma-range vibrotactile stimulation for 30 minutes, five days per week, over five weeks, concomitant with usual care.
Number of subjects: 50
Study: 28865940

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT) 24 IU
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 26537570

Group type: EXPERIMENTAL
Intervention: Regular telephone calls every 2 weeks and weekly text messages for 6 months (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 23010790

Group type: EXPERIMENTAL
Intervention: Antibiotics (amoxicillin with clavulanic acid) for 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 0
Study: 20086017

Group type: EXPERIMENTAL
Intervention: Chemokine receptor 1 antagonist BX 471
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 18159115

Group type: EXPERIMENTAL
Intervention: Whole-body periodic acceleration (2-3 Hz, +/-2.2 m/s2 for 45 min)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (sedentary)
Number of subjects: 26
Study: 16820546

Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg twice per day)
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg twice per day)
Number of subjects: 1025

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 1025
Study: 15156789

Group type: EXPERIMENTAL
Intervention: Perception of acceleration for leftward movements
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Improvement in unilateral neglect after 14 months
Number of subjects: 1

Group type: COMPARATOR
Intervention: Comparison with other patients
Number of subjects: 1
Study: 10782754

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7745771

Group type: EXPERIMENTAL
Intervention: Accelerated recombinant tissue‐type plasminogen activator (rt‐PA) plus IV heparin
Number of subjects: 40021

Group type: COMPARATOR
Intervention: Streptokinase plus either subcutaneous or intravenous (IV) heparin
Number of subjects: 40021

Group type: EXPERIMENTAL
Intervention: Combined streptokinase and rt‐PA plus IV heparin
Number of subjects: 40021

Group type: EXPERIMENTAL
Intervention: Enrollment in the United States
Number of subjects: 40021
Study: 2203214

Group type: EXPERIMENTAL
Intervention: Physical therapy (medical gymnastics)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perineal electrical stimulation
Number of subjects: 0
Study: 7019293

Group type: EXPERIMENTAL
Intervention: Rinkel injection therapy (RIT)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Histamine placebo
Number of subjects: 155
Study: 30085324

Group type: EXPERIMENTAL
Intervention: Adalimumab (active treatment)
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: HiSCR responders
Number of subjects: 629

Group type: COMPARATOR
Intervention: HiSCR non-responders
Number of subjects: 629
Study: 26970434

Group type: EXPERIMENTAL
Intervention: Web-based collaborative care intervention
Number of subjects: 261

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 261
Study: 24905929

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) - GaAlAs diode laser [780 nm, 30 mW continuous wave (CW), 0.785 cm(2), 38.2 mW/cm(2)], applied for 90 sec per point, 5 times per week for 2 weeks, followed by 10 treatments every other day for 3 weeks (total of 20 treatments)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (sham) laser treatment
Number of subjects: 79
Study: 22264667

Group type: EXPERIMENTAL
Intervention: First condom use period (FCs)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Second condom use period (FCs)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Third condom use period (FCs)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Final use of FC in the last period
Number of subjects: 170
Study: 20197530

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg once daily
Number of subjects: 3350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3350
Study: 18793528

Group type: EXPERIMENTAL
Intervention: Cinacalcet administered with the first major meal after dialysis
Number of subjects: 673

Group type: COMPARATOR
Intervention: Cinacalcet administered with food during the dialysis session
Number of subjects: 673
Study: 15921057

Group type: EXPERIMENTAL
Intervention: Case Method Learning (CML) intervention group
Number of subjects: 255

Group type: COMPARATOR
Intervention: Primary care control group
Number of subjects: 255

Group type: COMPARATOR
Intervention: External specialist control group
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: CML intervention group
Number of subjects: 255

Group type: COMPARATOR
Intervention: Specialist clinic group
Number of subjects: 255
Study: 11797179

Group type: EXPERIMENTAL
Intervention: lamivudine-zidovudine (150 mg/300 mg) combination tablet and one 300-mg abacavir tablet administered twice daily
Number of subjects: 108
Study: 9830895

Group type: EXPERIMENTAL
Intervention: Electrically controlled beds
Number of subjects: 782

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as standard care without electric beds)
Number of subjects: 782
Study: 8129119

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 50 micrograms
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with adrenaline 5 micrograms.ml‐1 (dose 40 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 30
Study: 2628746

Group type: EXPERIMENTAL
Intervention: meat vegetable dinner fortified with iron‐2‐sulfate (3 mg iron per 100 kcal)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: milk based rice cereal (MBRC) fortified with iron‐3‐pyrophosphate (3 mg iron per 100 kcal)
Number of subjects: 73

Group type: COMPARATOR
Intervention: non iron fortified vegetable potato dinner
Number of subjects: 73
Study: 9890789

Group type: EXPERIMENTAL
Intervention: sulthiame
Number of subjects: 22

Group type: COMPARATOR
Intervention: diphenylhydantoin
Number of subjects: 22
Study: 31000477

Group type: EXPERIMENTAL
Intervention: VRC01 (40 mg/kg) intravenously every 3 weeks for up to 24 weeks during analytic interruption of ART
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (saline) intravenously every 3 weeks for up to 24 weeks during analytic interruption of ART
Number of subjects: 19
Study: 29125783

Group type: EXPERIMENTAL
Intervention: Knowledge intervention
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Empowerment intervention
Number of subjects: 201
Study: 26487008

Group type: EXPERIMENTAL
Intervention: Glucose ingestion (1.7 g/min)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sucrose ingestion (1.7 g/min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Water ingestion (control)
Number of subjects: 14
Study: 23553291

Group type: COMPARATOR
Intervention: Balloon kyphoplasty
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vertebral body stenting
Number of subjects: 100
Study: 22230405

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil
Number of subjects: 240

Group type: COMPARATOR
Intervention: Wild-type (A118A) patients
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: A118G carriers
Number of subjects: 240
Study: 18573809

Group type: EXPERIMENTAL
Intervention: Inhalation treatment through a face mask
Number of subjects: 172

Group type: COMPARATOR
Intervention: Other interventions (Control)
Number of subjects: 172
Study: 16720496

Group type: EXPERIMENTAL
Intervention: Cytostatic drug treatment close to surgery
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (neurologically impaired children)
Number of subjects: 54
Study: 15587929

Group type: EXPERIMENTAL
Intervention: Teicoplanin (TEI) administered with three 10 mg/kg Q12h loading infusions, and maintenance with 10 mg/kg or 15 mg/kg Q24h
Number of subjects: 20
Study: 11412732

Group type: EXPERIMENTAL
Intervention: Intradural-epidural analgesia (IEA) - 25 microgram of intradural fentanyl with 2.5 mg of isobaric bupivacaine with adrenalin, followed by 8 mL bolus of 0.125% bupivacaine at 8 ml/h
Number of subjects: 42

Group type: COMPARATOR
Intervention: Continuous epidural analgesia (CEA) - 8 ml of 0.25% bupivacaine with adrenalin, followed by perfusion of 0.125% bupivacaine and 1 microgram/ml of fentanyl at 8 ml/h
Number of subjects: 42
Study: 9407424

Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 583

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 583
Study: 7705386

Group type: EXPERIMENTAL
Intervention: 1 mg 17 beta-oestradiol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 2651054

Group type: EXPERIMENTAL
Intervention: Chronic magnesium supplementation (2 g/day)
Number of subjects: 8
Study: 920124

Group type: EXPERIMENTAL
Intervention: Transverse technique (47 cases)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sagittal technique (41 cases)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 88
Study: 31567305

Group type: EXPERIMENTAL
Intervention: Counseling and auricular acupressure
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Counseling and placebo acupressure
Number of subjects: 109

Group type: COMPARATOR
Intervention: Self-help for smoking cessation (control)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 109
Study: 31331968

Group type: EXPERIMENTAL
Intervention: Dalfampridine 10 mg twice daily for 12 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 28143388

Group type: EXPERIMENTAL
Intervention: Cardiac telerehabilitation using a patient-centred web application
Number of subjects: 300

Group type: COMPARATOR
Intervention: Centre-based cardiac rehabilitation
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Cardiac telerehabilitation
Number of subjects: 300
Study: 23774117

Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil (PR)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sevoflurane-sufentanil (SS)
Number of subjects: 66
Study: 22280901

Group type: EXPERIMENTAL
Intervention: Aged garlic extract (2.56 g/d)
Number of subjects: 120
Study: 20374102

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment based on TCM pattern diagnosis
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 16
Study: 18471327

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15767619

Group type: COMPARATOR
Intervention: L-thyroxine, 100 microg/d (standard treatment)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: L-thyroxine, 75 microg/d plus liothyronine, 5 microg/d (combination treatment)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: L-thyroxine, 87.5 microg/d plus liothyronine, 7.5 microg/d (add-on combination treatment)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 28
Study: 12627307

Group type: EXPERIMENTAL
Intervention: Maximal aerobic exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: Resting FBF
Number of subjects: 24
Study: 10570752

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-3 (rhIL-3) administered subcutaneously at a dose of 5 micrograms/kg once a day for 10 days starting from day 4 of chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-3 (rhIL-3) administered subcutaneously at a dose of 10 micrograms/kg once a day for 10 days starting from day 4 of chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control observation period (no rhIL-3 administration)
Number of subjects: 0
Study: 7818124

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Atracurium 0.3 mg/kg
Number of subjects: 50
Study: 2370107

Group type: EXPERIMENTAL
Intervention: Conjugates composed of Streptococcus pneumoniae type 12F polysaccharide covalently coupled to diphtheria toxoid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pnu-Imune (23-valent pneumococcus vaccine)
Number of subjects: 0
Study: 517882

Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol (THC), 15 mg orally three times a day
Number of subjects: 116

Group type: COMPARATOR
Intervention: Prochlorperazine, 10 mg orally three times a day
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 29882038

Group type: EXPERIMENTAL
Intervention: Intensive health guidance focusing on eating quickly
Number of subjects: 141

Group type: COMPARATOR
Intervention: Standard health guidance about MetS
Number of subjects: 141
Study: 31535520

Group type: EXPERIMENTAL
Intervention: Dexamethasone (group A, n=61)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo (group B, n=61)
Number of subjects: 122
Study: 29806390

Group type: EXPERIMENTAL
Intervention: Rapid prototyping (RP) technology for nasoalveolar molding (NAM) appliances
Number of subjects: 39

Group type: COMPARATOR
Intervention: Traditional NAM protocol
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 39
Study: 25714798

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV23)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control PPV23
Number of subjects: 1200
Study: 23474309

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified diet
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Breast-feeding duration
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Breast-feeding duration adjustment
Number of subjects: 597
Study: 21863031

Group type: EXPERIMENTAL
Intervention: Screening every year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Screening every 3 years
Number of subjects: 0
Study: 19811593

Group type: EXPERIMENTAL
Intervention: Academic detailing plus postal prescribing feedback (AD)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Postal prescribing feedback (PB)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cost-effectiveness of postal prescribing feedback service
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of prescriber adviser service
Number of subjects: 98
Study: 16758905

Group type: EXPERIMENTAL
Intervention: Bacterial lysate [see text]PC‐19
Number of subjects: 0
Study: 15276139

Group type: EXPERIMENTAL
Intervention: QEEG analysis
Number of subjects: 35
Study: 11716835

Group type: EXPERIMENTAL
Intervention: English-speaking children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Japanese-speaking children
Number of subjects: 0
Study: 9156374

Group type: COMPARATOR
Intervention: Dichloroacetate (50 mg/kg) administered via 30-minute intravenous infusion
Number of subjects: 111
Study: 8395087

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (1.3 Gy twice daily for five weeks, total dose 65 Gy)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional radiotherapy (2.0 Gy daily for six weeks, total dose 60 Gy)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 68
Study: 2441166

Group type: EXPERIMENTAL
Intervention: Transdermal clonidine patches (2.5 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 28927484

Group type: EXPERIMENTAL
Intervention: Telephone-based Behavioral Health Laboratory (BHL) assessment
Number of subjects: 108

Group type: COMPARATOR
Intervention: In-person Behavioral Health Laboratory (BHL) assessment
Number of subjects: 108
Study: 27447693

Group type: EXPERIMENTAL
Intervention: Student-only intervention
Number of subjects: 2801

Group type: EXPERIMENTAL
Intervention: Combined student-parent intervention
Number of subjects: 2801

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2801

Group type: EXPERIMENTAL
Intervention: Student-parent intervention
Number of subjects: 2801
Study: 23677620

Group type: EXPERIMENTAL
Intervention: 3D‐PCASL
Number of subjects: 30

Group type: COMPARATOR
Intervention: SE‐DSC
Number of subjects: 30

Group type: COMPARATOR
Intervention: GE‐DSC
Number of subjects: 30
Study: 22638779

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 178

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 178
Study: 20823351

Group type: EXPERIMENTAL
Intervention: Labeling message
Number of subjects: 97

Group type: COMPARATOR
Intervention: Generic (no label) message
Number of subjects: 97
Study: 19082319

Group type: EXPERIMENTAL
Intervention: No Touch (NT) technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 20
Study: 16170291

Group type: EXPERIMENTAL
Intervention: Topical treatment with DRNA 5 mg vaginal suppositories for 15 days monthly, reduced gradually thereafter
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 220
Study: 12511763

Group type: EXPERIMENTAL
Intervention: Statistical models to predict stroke outcomes
Number of subjects: 2955
Study: 10988188

Group type: EXPERIMENTAL
Intervention: LABD plus exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LABD plus exercise plus IMT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LABD
Number of subjects: 30
Study: 8772549

Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg orally at -270 min and 250 mg at -60 min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acipimox with Pyridostigmine (120 mg orally at -60 min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acipimox with GHRH (1 microgram/kg, iv at 0 min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acipimox with GHRP-6 (1 microgram/kg, iv at 0 min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acipimox with GHRH plus GHRP-6
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 1728249

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP; 0.5 mg/kg orally)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: fenfluramine hydrochloride (60 mg orally)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: fenfluramine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP) and fenfluramine
Number of subjects: 30
Study: 6372935

Group type: EXPERIMENTAL
Intervention: Pre-operative percutaneous transhepatic biliary drainage (PTBD) followed by laparotomy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pre-operative PTBD
Number of subjects: 65
Study: 30653344

Group type: EXPERIMENTAL
Intervention: Cell-seeded scaffold
Number of subjects: 33

Group type: COMPARATOR
Intervention: Scaffold alone
Number of subjects: 33
Study: 30431004

Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg daily for 1 week (n = 93)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg daily for 2 weeks (n = 109)
Number of subjects: 202
Study: 27281490

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 40
Study: 24245778

Group type: EXPERIMENTAL
Intervention: Intention measurement condition (participants reported their intentions to eat healthy foods)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control conditions (two control groups)
Number of subjects: 151
Study: 22226937

Group type: EXPERIMENTAL
Intervention: Walking while texting on a cell phone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Walking while talking on a cell phone
Number of subjects: 33

Group type: COMPARATOR
Intervention: Walking without cell phone use (baseline)
Number of subjects: 33
Study: 19616880

Group type: EXPERIMENTAL
Intervention: Explosive anger episodes (defined as one attack of explosive anger a month)
Number of subjects: 1544

Group type: EXPERIMENTAL
Intervention: High levels of trauma exposure
Number of subjects: 1544

Group type: EXPERIMENTAL
Intervention: Latent class analysis
Number of subjects: 1544

Group type: EXPERIMENTAL
Intervention: Post-traumatic stress and general psychological distress
Number of subjects: 1544
Study: 17614750

Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 585

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 585
Study: 15357156

Group type: EXPERIMENTAL
Intervention: IV administration set changed on day 4 (n = 203)
Number of subjects: 251

Group type: COMPARATOR
Intervention: IV administration set not changed (n = 201)
Number of subjects: 251
Study: 11394609

Group type: EXPERIMENTAL
Intervention: Anterior cruciate ligament-reconstructed knee
Number of subjects: 25

Group type: COMPARATOR
Intervention: Uninjured knee
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (20 uninjured age- and activity-matched subjects)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Patients (ACL-reconstructed)
Number of subjects: 25